RWM
ORMP icon

Ritholtz Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Ritholtz Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$529K Buy
+155,479
New +$527K 0.01% 772

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ritholtz Wealth Management's ORMP Position: Q1 2026 in Review

Ritholtz Wealth Management opened a new position in Oramed Pharmaceuticals (ORMP) in Q1 2026: 155,479 shares worth $529K. The stake represents 0.01% of the portfolio and ranks #772 among its holdings.

64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Ritholtz Wealth Management held 155,479 shares of Oramed Pharmaceuticals worth $529K as of Q1 2026.
  • Oramed Pharmaceuticals was a new Ritholtz Wealth Management position in Q1 2026.
  • Oramed Pharmaceuticals made up 0.01% of Ritholtz Wealth Management's portfolio in Q1 2026, its #772 holding.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Ritholtz Wealth Management's 13F filing for Q1 2026, filed 20 Apr 2026.